No. of Recommendations: 2
And I pretty muuch said it's a beginning... and ...
"Eli Lilly announced they are lowering the cost of insulin by 70% and capping what patients pay out-of-pocket for insulin at $35. This action, driven by the momentum from the Inflation Reduction Act, could benefit millions of Americans with diabetes in all fifty states and U.S. territories. The President continues to call on Congress to finish the job and cap costs at $35 for all Americans."
There, as of March 2
https://www.whitehouse.gov/briefing-room/statement...Eli Lilly & Co. is capping out-of-pocket costs for insulin at $35 a month, following a public plea from President Joe Biden for lower prices of the diabetes treatment for all Americans.
Lilly announced the cap Wednesday along with other actions, including cutting the list price for non-branded Insulin Lispro Injection to $25 a vial in May, while some Humalog and Humulin doses will be slashed 70% in the fourth quarter. Newly-launched Rezvoglar will sell at a 78% discount to a biosimilar version ' Sanofi's Lantus ' starting in April, the company said.
https://news.bloomberglaw.com/health-law-and-busin...SO THE ANSWER IS YES to your 1 & 2.I'll ignore you other question.
